Abstract:The gold standard therapy for muscle-invasive bladder cancer (MIBC) is neoadjuvant chemotherapy followed by radical cystectomy (RC) and urinary diversion. Some patients may have their disease completely eradicated by chemotherapy as ~35% of patients achieve a pathologic complete response (pCR) when evaluated from RC specimens. RC with urinary diversion is a life-altering operation with high complication rates and therefore determining who are complete responders would improve quality of life and could decrease costs and still achieve a high cure rate via RC avoidance. Unfortunately, current methods cannot accurately identify complete responders. Our lab has developed a urine-based liquid biopsy test in which DNA isolated from urine and germline is isolated and subjected to panel exome sequencing for enumeration of somatic variants. This occurs under the premise that tumor DNA identified (as mutant alleles) is a marker of residual disease while the absence of tumor DNA (meaning the absence of mutant alleles) can indicate a pCR. A 55 gene panel was designed to be used for exonic sequencing of urinary DNA (uDNA) to identify mutations indicative of bladder cancer or therapeutic targets. We have shown that most mutations in tumor tissue are detectable as mutations in urine (Mu). We also showed that the presence or absence of residual Mu after completion of chemotherapy strongly associates with residual disease or pCR at the time of RC, respectively. Therefore, this test could be used after neoadjuvant therapy to better identify patients for RC avoidance. To optimize this test, we are currently evaluating pre-analytical factors affecting the yield, purity, and integrity of uDNA and the quality of sequencing data using prospectively collected samples from patients with MIBC. We are also testing commercial and novel preservatives to identify one that maintains cell-free DNA integrity, yield, and mutation detection accuracy to enable temporary ambient temperature storage without compromising mutation detection, permitting shipping/centralized testing. Lastly, we are comparing two library preparation approaches: classical hybrid capture-based (Agilent SureSelect XTHS) and amplicon+hybrid capture-based (Agilent HaloPlexHS) to determine which performs the best for identifying the variants in a sample. Our results showed that both sequencing depth and the quality bases mapped was higher when utilizing the SureSelect XTHS kit as compared to HaloPlexHS using approximately the same number of reads. This improvement may also increase the power to detect rare alleles. Studies described herein will enable liquid biopsy tests to accurately identify patients with pCR after neoadjuvant therapy and might safely avoid radical cystectomy. Citation Format: Rhea Arya, Henkel Valentine, Uttam Satyal, Raju Chelluri, Mengmeng Li, Philip Abbosh. Urine-based liquid biopsy test for the detection of residual bladder cancer in radical cystectomy patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3701.

Quantitative RNA Analysis from Urine Using Real Time PCR

Specific Detection of Prostate Cancer Cells in Urine by RNA In Situ Hybridization

Extracellular RNAs from Whole Urine to Distinguish Prostate Cancer from Benign Prostatic Hyperplasia

Deconvolution of Human Urine across the Transcriptome and Metabolome

Next Generation Sequencing of urine exfoliated cells: an approach of prostate cancer microRNAs research

Trans-Renal Cell-Free Tumor DNA for Urine-Based Liquid Biopsy of Cancer

Detecting and monitoring bladder cancer with exfoliated cells in urine

Urine miRNA signature as a potential non-invasive diagnostic and prognostic biomarker in cervical cancer

Urinary Biomarkers for Prostate Cancer

The potential use of urine cell free DNA as a marker for cancer

Abstract LB105: Sensitive urothelial cancer detection via high volume urine DNA analysis

Abstract 332: Improved high-throughput genomic analysis of urine samples using pixelated-ultrasound to enable personalized genomic profiling and therapeutic developments in cancer

Unlocking the potential of tumor‐derived DNA in urine for cancer detection: methodological challenges and opportunities

Gene-Transcript Expression in Urine Supernatant and Urine Cell-Sediment Are Different but Equally Useful for Detecting Prostate Cancer

Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery

Exploring a Desirable Quadr-mRNAs Panel for Non-invasive and Ultrasensitive Bladder Cancer Diagnosis: In-silico and Clinical Studies

Current challenges and best practices for cell-free long RNA biomarker discovery

A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization

Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers

Abstract 3701: Urine-based liquid biopsy test for the detection of residual bladder cancer in radical cystectomy patients

Urinary extracellular vesicles miRNA—A new era of prostate cancer biomarkers